Esperion Therapeutics Inc

Esperion Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes medicines for patients with elevated low-density lipoprotein cholesterol (LDL-C) in the United States. Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets, which are oral, once-daily, non-statin medicines for primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or cardiovascular disease who require additional LDL-C lowering. Other products include NILEMDO, an ATP citrate lyase (ACL) inhibitor, and NUSTENDI, a bempedoic acid and ezetimibe tablet. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd., Otsuka Pharmaceutical Co., Ltd., and Daiichi Sankyo Europe GmbH. Formerly known as HDL Therapeutics, Inc., it changed its name to Esperion Therapeutics, Inc. in May 2008, was incorporated in 2008, and is headquartered in Ann Arbor, Michigan.